08:09 AM EDT, 06/11/2025 (MT Newswires) -- Nvidia ( NVDA ) said Wednesday that it is collaborating with Novo Nordisk ( NVO ) to advance drug discovery by using artificial intelligence.

The partnership supports Novo Nordisk's ( NVO ) agreement with DCAI to use the Gefion AI supercomputer, which is powered by Nvidia DGX SuperPOD and provides an AI factory for running drug discovery and agentic AI workloads, according to Nvidia ( NVDA ).

The companies plan to build customized AI models and agents that Novo Nordisk ( NVO ) can use for early research and clinical development, Nvidia ( NVDA ) said, adding they also plan to use advanced simulation and physical AI technologies.